|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.|
|Rapid review commissioned||01/06/2010|
|Rapid review completed||22/06/2010|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.